Avingtrans subsidiary Booth secures £4.5m HS2 contract

Avingtrans

Avingtrans Plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced its subsidiary Booth Industries (Booth), has secured a new £4.5 million contract to supply pressure-rated fire doors for HS2.

The contract expands upon Booth Industries’ involvement in the HS2 project, following the £36 million contract secured in September 2020 to supply cross passage doors for the London-to-West Midlands segment of the route. Booth will begin mass production of the cross-passage sliding doorsets in its 600m², state-of-the-art production cell during 2025.

Following the initial HS2 contract, Booth developed tested doors capable of withstanding high pressure shockwaves across more than 5 million cycles, delivering a design life exceeding 30 years. This proven innovation and expertise are now being applied to bespoke designs for the newly awarded pressure-door contract.

Austen Adams, divisional managing director of Avingtrans’ AES division, commented:

“The new contract is fantastic news for Booth and represents a significant step forward for the business. Both sets of safety doors will play a crucial role in the operation of the railway, sealing off passageways between tunnels and providing access in case of emergency.

“With trains capable of travelling at speeds of up to 250mph passing within metres of the doors, they not only need to provide reliable fire integrity and insulation but also to withstand a wide range of challenging day-to-day environmental and fatigue pressures. Both doorsets have already set new benchmarks for the industry and we are delighted to see Booth reinforcing its position as an innovator in the sector, developing specialist products with genuine global market potential.”

Share on:

Latest Company News

Avingtrans appoints Stuart Gall as CEO of Medical and Industrial Imaging division

Avingtrans plc has announced that Stuart Gall officially assumed the role of Chief Executive Officer of its medical and industrial imaging division on 1 January 2026.

Avingtrans subsidiary Adaptix gains FDA clearance for Ortho350

Avingtrans reported that its subsidiary Adaptix has received FDA 510(k) clearance for the Ortho350, a compact 3D orthopaedic imaging system designed for point of care use.

Avingtrans CEO on record revenue and strong order book momentum for FY25 (LON:AVG)

Avingtrans has delivered record revenue of £156.4 million for FY25, with Chief Executive Officer Steve McQuillan highlighting robust order book growth, major contract wins, and increasing demand across energy, defence, infrastructure and medical divisions.

Avingtrans appoints Stuart Gall as CEO of medical imaging division

Avingtrans Plc has announced the appointment of Stuart Gall as Divisional Chief Executive Officer of its medical imaging businesses, including Adaptix and Magnetica, effective on or before 10 March 2026.

Avingtrans Plc Record Results, New Nuclear Wins and the Power of AI-Driven Demand (Video)

Avingtrans CEO Steve McQuillan shares how AI, energy and infrastructure megatrends are driving record results — and why strategic deals could be back on the table in FY26.

Avingtrans reports record revenue and earnings growth in FY25

Avingtrans posted preliminary results for the year ended 31 May 2025, with revenue up 14.5% to a record £156.4m and adjusted EBITDA rising to £16.7m. Adjusted profit before tax increased 18% to £8.6m, while diluted EPS grew 28% to 23.7p.

    Search

    Search